Compare CCO & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CCO | NVAX |
|---|---|---|
| Founded | 1995 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Advertising | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.3B |
| IPO Year | 2005 | 1996 |
| Metric | CCO | NVAX |
|---|---|---|
| Price | $2.40 | $8.08 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 5 | 9 |
| Target Price | $2.12 | ★ $11.33 |
| AVG Volume (30 Days) | ★ 4.4M | 2.7M |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 110.81 | ★ 309.76 |
| EPS | 0.04 | ★ 2.58 |
| Revenue | ★ $1,604,140,000.00 | $1,123,479,000.00 |
| Revenue This Year | $5.35 | N/A |
| Revenue Next Year | $4.26 | N/A |
| P/E Ratio | $59.75 | ★ $3.12 |
| Revenue Growth | 6.57 | ★ 64.69 |
| 52 Week Low | $1.00 | $5.80 |
| 52 Week High | $2.43 | $11.85 |
| Indicator | CCO | NVAX |
|---|---|---|
| Relative Strength Index (RSI) | 56.10 | 41.70 |
| Support Level | $2.37 | $7.70 |
| Resistance Level | $2.41 | $9.02 |
| Average True Range (ATR) | 0.01 | 0.29 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 60.00 | 26.95 |
Clear Channel Outdoor Holdings Inc is a provider of out-of-home advertising solutions. The company offers advertisers an opportunity to reach mass audiences across various high-traffic public spaces, by using its diverse portfolio of assets including roadside billboards, street furniture, and airport displays. Its reportable segments are; America (U.S. operations excluding airports), Airports (U.S. and Caribbean airport operations), and Other. A majority of its revenue is generated from the America segment which generates revenue from the sale of advertising on printed and digital out-of-home advertising displays such as bulletins, posters, street furniture, and others. Geographically, the company generates maximum revenue from the United States followed by Singapore.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.